The Comparative Effects of Valsartan and Amlodipine on Vascular Microinflammation in Newly Diagnosed Hypertensive Patients

References

• Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17(4):223–230.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Lawlor DA, Harbord R, . Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25(5):1051–1056.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53(1):95–102.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. J Assoc Physicians 2003; 96(11):793–807.
   Google Scholar
• Bottazzi B, Vouret-Craviari V, Bastone A, . Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272(52):32817–32823.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Peri G, Delneste Y, . The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204(4):793–804.
   PubMed Web of Science ®Google Scholar
• Harrison DG, Guzik TJ, Lob HE, . Inflammation, immunity, and hypertension. Hypertension 2011; 57(2):132–140.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, . 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Euro Heart J 2007; 28(12):1462–1536.
   PubMed Web of Science ®Google Scholar
• Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens 2007; 9(2):103–112.
   PubMedGoogle Scholar
• Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Human Hypertens 1991; 5(Suppl 1):61–66.
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, . The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc 2003; 289(19):2560–2572.
   PubMed Web of Science ®Google Scholar
• Morillas P, de Andrade H, Castillo J, . Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Rev Esp Cardiol 2012; 65(9):819–825.
   PubMed Web of Science ®Google Scholar
• Fazzini F, Peri G, Doni A, . PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44(12):2841–2850.
   PubMed Web of Science ®Google Scholar
• Yano Y, Hatakeyama K. Inflammation and hypertension: new clinical information on pentraxin-3. Anadolu Kardiyol Derg 2012; 12(4):305–306.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Bottazzi B, . The long pentraxin PTX3 in vascular pathology. Vasc Pharmacol 2006; 45(5):326–330.
   PubMed Web of Science ®Google Scholar
• Tong M, Carrero JJ, Qureshi AR, . Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2(5):889–897.
   PubMed Web of Science ®Google Scholar
• Parlak A, Aydoğan U, Iyisoy A, . Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg 2012; 12(4):298–304.
   PubMed Web of Science ®Google Scholar
• Parlak A, Iyisoy A, Aydogan U, Cakir E, Saglam K. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients. Med Hypotheses 2012; 79(3):294–298.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Carrero JJ, Martín-Ventura JL, . Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5(7):1174–1181.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3):646–661.
   PubMed Web of Science ®Google Scholar
• Marfella R, Siniscalchi M, Nappo F, . Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18(3):308–318.
   PubMed Web of Science ®Google Scholar
• Moubarak M, Jabbour H, Smayra V, . Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol Res 2012; 61(1):13–24.
   PubMed Web of Science ®Google Scholar
• Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am College Cardiol 2001; 37(2):440–444.
   PubMed Web of Science ®Google Scholar
• Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46(6):735–739.
   PubMed Web of Science ®Google Scholar
• Suleyman H, Halici Z, Hacimuftuoglu A, Gocer F. Role of adrenal gland hormones in antiinflammatory effect of calcium channel blockers. Pharmacol Rep 2006; 58(5):692–699.
   PubMed Web of Science ®Google Scholar
• Kataoka C, Egashira K, Ishibashi M, . Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 2004; 286(2):H768–H774.
   PubMed Web of Science ®Google Scholar
• Shishido T, Konta T, Nishiyama S, . Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin Exp Hypertens 2011; 33(2):117–123.
   PubMed Web of Science ®Google Scholar
• Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Fail 2010; 32(8):903–912.
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008; 30(3):267–276.
   PubMed Web of Science ®Google Scholar
• Yoshii T, Iwai M, Li Z, . Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29(6):457–466.
   PubMed Web of Science ®Google Scholar
• Martín-Ventura JL, Muñoz-Garcia B, Blanco-Colio LM, . Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl 2008;111:S71–S74.
   PubMedGoogle Scholar